Krystal Biotech, Inc (KRYS)

Etorro trading 970x250
Krystal Biotech, Inc (KRYS) Logo

About Krystal Biotech, Inc

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203

Krystal Biotech, Inc News and around…

Latest news about Krystal Biotech, Inc (KRYS) common stock and company :

KRYS Crosses Above Key Moving Average Level
27 May, 2022 FinancialContent

In trading on Friday, shares of Krystal Biotech Inc (KRYS) crossed above their 200 day moving average of $60.21, changing hands as high as $60.98 per share. Krystal Biotech Inc shares are currently trading up about 7.2% on the day..

Krystal Biotech Stock Flashes Renewed Technical Strength
23 May, 2022 FinancialContent

A Relative Strength Rating upgrade for KrystalBiotech shows improving technical performance.

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
19 May, 2022 Yahoo! Finance

PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)” at the Society for Investigative Dermatology 2022 Annual Meeting, taking place May 18-21 in Portland, Oregon. Krystal Presentation GEM-3: phase 3 safety a

Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
09 May, 2022 Yahoo! Finance

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
03 May, 2022 Yahoo! Finance

PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare Conference. Details for the event are as follows: Bank of America Merrill Lynch Global Healthcare Conference Date: Tuesday, May 10, 2022Time: 9:20am PDTWebcast Link: https://bofa.veracast.com/webcasts/bofa/hc2022

Jeune Aesthetics Announces Formation and Members of Scientific Advisory Board
28 Apr, 2022 Yahoo! Finance

April 28, 2022Download PDF PITTSBURGH, April 28, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune Aesthetics”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced the formation and members of its Scientific Advisory Board, comprised of industry leaders to serve as strategic advisors assisting with program strategy and clinical development. "I am immensely proud of the Scientific Advisory Board that we’ve assembled," said Bhushan Hardas, M.D., Pre

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
14 Apr, 2022 FinancialContent

KrystalBiotech sees its Relative Strength Rating enter the elite 90-plus level.

Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
11 Apr, 2022 Yahoo! Finance

PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study, the opportunity to be dosed in their homes by a health care professional (HCP). Krystal is offering this convenience to patients based on feedback from the U.S. Food and Drug Administration (FDA) following review

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
07 Apr, 2022 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
28 Mar, 2022 Yahoo! Finance

Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in patients with recessive dystrophic epidermolysis bullosa (RDEB) compared with placebo with minimal adverse events PITTSBURGH, March 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that results f

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
26 Mar, 2022 Yahoo! Finance

PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB), at the 2022 American Academy of Dermatology Annual Meeting in Boston, Mass. The data was presented by Peter Marinkovich, M.D., Director of

Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
24 Mar, 2022 Yahoo! Finance

PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and Guggenheim’s 3rd Annual Genomic Medicines and Rare Disease Day. Details for the events are as follows: H.C. Wainwright Gene Therapy and Gene Editing ConferencePresentation Date: Wednesday, March 30, 2022

10 Healthcare Stocks to Buy Today According to Steven Cohen’s Point72 Asset Management
22 Mar, 2022 Yahoo! Finance

In this piece we will take a look at the 10 healthcare stocks to buy today according to Steven Cohen’s Point72 Asset Management. If you aren’t interested in the billionaire hedge fund owner’s background or the fund’s profile and want to jump straight to its top healthcare stock picks, then head over to 5 Healthcare […]

Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
18 Mar, 2022 Yahoo! Finance

PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-breaking research at the 2022 American Academy of Dermatology Annual Meeting, taking place March 25-29 in Boston, Mass. “We look forward to sharing additional results from Krystal’s Phase 3 study of the clinical efficacy and safety of beremagene geperpavec (B-VEC) for the treatment of dystrophic epide

Two Pittsburgh biotech firms settle trade-secret lawsuit
15 Mar, 2022 Yahoo! Finance

Krystal Biotech Inc. announced Tuesday it will pay $25 million and potentially tens of millions more later to settle a trade secret lawsuit filed against it by another Pittsburgh-based biotech company, PeriphaGen, back in May 2020. PeriphaGen filed suit against Krystal Biotech in U.S. District Court for the Western District of Pennsylvania, alleging that Krystal misused trade secrets and confidential information after a Krystal and PeriphaGen business relationship broke down in 2017. The lawsuit had been going through the courts before Tuesday's announcement, which is that both Krystal (NASDAQ: KRYS) and PeriphaGen signed a binding term sheet.

Krystal Biotech Announces Settlement with PeriphaGen, Inc.
15 Mar, 2022 Yahoo! Finance

PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding term sheet with PeriphaGen, Inc. (“PeriphaGen”) to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020. Under the conditions of the term sheet, which are legally binding, Krystal will receive all of PeriphaGen’s biological materials and skin assets and will pay Peripha

Krystal Biotech (KRYS) Shares Cross Below 200 DMA
03 Mar, 2022 FinancialContent

In trading on Thursday, shares of Krystal Biotech Inc (KRYS) crossed below their 200 day moving average of $60.32, changing hands as low as $58.20 per share. Krystal Biotech Inc shares are currently trading down about 9.3% on the day..

Investors Snag KRYS 15.8% Cheaper Than Its Secondary Stock Offering
02 Mar, 2022 FinancialContent

Looking back to 92 days ago, Krystal Biotech Inc (KRYS) priced a 2,666,667 share secondary stock offering at $75.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Recap: Krystal Biotech Q4 Earnings
28 Feb, 2022 FinancialContent

Krystal Biotech (NASDAQ:KRYS) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what ...

Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
28 Feb, 2022 Yahoo! Finance

Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H 2022Phase 1 trial of KB407 in cystic fibrosis patients in Australia expected to begin in 1H 2022; IND filing and U.S. trial initiation anticipated in 2H 2022Jeune Aesthetics on track to announce Phase 1 proof-of-concept efficacy data from KB301, being developed for aesthetic indications, in 1Q 2022Stron

Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
24 Feb, 2022 Yahoo! Finance

PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference, which is taking place virtually March 7-9, 2022. Details are as follows: Fireside Chat Date:Monday, March 7, 2022Fireside Chat Time:2:50-3:20 p.m. ESTWebcast link:https://wsw.com/webcast/cowen108/krys/2056

Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ...
03 Feb, 2022 Yahoo! Finance

Investment company Act Capital Management, Llc (Current Portfolio) buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, AirSculpt Technologies Inc, enVVeno Medical Corp, sells , Upstart Holdings Inc, Affirm Holdings Inc, Nektar Therapeutics, Nuance Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Act Capital Management, Llc.

2 Biotech Stocks That Could Skyrocket This Year
02 Feb, 2022 FinancialContent

For these two companies, the rewards could end up outweighing the risks.

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise
18 Jan, 2022 FinancialContent

Krystal BiotechInc(NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA ...

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
18 Jan, 2022 FinancialContent

Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:FSM) from Hold to Buy. For the third ...

Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
18 Jan, 2022 Yahoo! Finance

PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, includin

Could This Soaring Biotech Stock Make You Rich?
15 Dec, 2021 FinancialContent

This company has made quite a lot of noise recently.

Why Krystal Biotech's Shares Rose More Than 77% This Week
02 Dec, 2021 FinancialContent

The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease.

Investors Bag KRYS 8.2% Lower Than Its Secondary Stock Offering
02 Dec, 2021 FinancialContent

Looking back to 2 days ago, Krystal Biotech Inc (KRYS) priced a 2,666,667 share secondary stock offering at $75.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Why Krystal Biotech Stock Is Retreating Today
01 Dec, 2021 FinancialContent

A public offering is weighing on the biotech's shares today.

Krystal Biotech, Inc (KRYS) is a NASDAQ Common Stock listed in , ,

970x250